This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neuro-otology  • Hearing Loss/ Deafness  • Alert me on articles by topic  Social Bookmarking   What's this?

Hisham Zeitoun, MPhil, FRCS; Jennifer Gray Beckman, JD; H. Alexander Arts, MD; Christopher D. Lansford, MD; David S. Lee, MD; Hussam K. El-Kashlan, MD; Steven A. Telian, MD; Dawn E. Denny, BS; Anna Ramakrishnan, MS; Thankam S. Nair, MS; Michael J. Disher, MD; Robert T. Sataloff, MD; Susan G. Fisher, PhD; Thomas E. Carey, PhD

Arch Otolaryngol Head Neck Surg. 2005;131:665-672.

Objective  To determine whether antibodies to supporting cells are associated with response to corticosteroids in patients with autoimmune sensorineural hearing loss.

Design  Prospective analysis of antibody to inner-ear antigens.

Setting  Collaborating otology practices in Pennsylvania, Michigan, and Indiana.

Patients  Sixty-three patients with rapidly progressive unilateral or bilateral sensorineural hearing loss of unknown cause suggestive of autoimmune sensorineural hearing loss.

Interventions  Pretreatment audiometry, serum analysis by Western blot (WB) and immunofluorescence (IF) tests, corticosteroid therapy, and follow-up audiometry.

Main Outcome Measures  Antibody reactivity and audiogram changes were analyzed for association with response to treatment.

Results  More than half of the patients (37/63) had antibodies to both a 68- to 72-kDa protein and to inner-ear supporting cells, 16 patients had positive results on one assay only, and 10 had negative results on both. Twenty-eight patients improved and 35 did not. The WB findings did not correlate with response. Of the WB-positive patients, 49% (21/43) improved, as did 35% (7/20) of the WB-negative patients (P = .30). In contrast, 53% (25/47) of IF-positive patients improved, compared with only 19% (3/16) in the IF-negative group (P = .02). Of those who improved, 89% (25/28) were IF positive.

Conclusions  Antibody to an inner-ear supporting cell antigen was significantly associated with hearing improvement after corticosteroid therapy (relative rate, 2.8). Patients with IF-positive serum are nearly 3 times more likely to experience improved hearing with corticosteroid treatment than those who are IF negative. Antibodies to inner-ear supporting cell antigen may have value in diagnosis and treatment of patients with autoimmune sensorineural hearing loss.

Author Affiliations: Department of Otolaryngology/Head and Neck Surgery (Drs Zeitoun, Arts, Lansford, Lee, El-Kashlan, Telian, and Disher) and Laboratory of Cell Biology and Immunology, Kresge Hearing Research Institute, Department of Otolaryngology/Head and Neck Surgery (Drs Beckman, Lansford, Lee, and Carey and Mss Denny, Ramakrishnan, and Nair), University of Michigan, Ann Arbor; Department of Otolaryngology, Thomas Jefferson University, Philadelphia, Pa (Dr Sataloff); Division of Epidemiology, University of Rochester, Rochester, NY (Dr Fisher); ENT Department, Glan Clwyd Hospital, Bodelwyddan, nr Rhyl, Wales (Dr Zeitoun); Finnegan, Henderson, Farbow, Garret & Dunner LLP, Washington, DC (Dr Beckman); Otolaryngology/Head and Neck Surgery Ltd, Milwaukee, Wis (Dr Lee); Merck & Co Inc, West Point, Pa (Ms Denny); and Ear, Nose and Throat Associates PC, Fort Wayne, Ind (Dr Disher).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?